These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34924264)

  • 1. A growing trend: CFTR modulators for cystic fibrosis lung transplant recipients.
    Hayes D; Sharma NS
    J Heart Lung Transplant; 2022 Feb; 41(2):127-128. PubMed ID: 34924264
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFTR modulator use in post lung transplant recipients.
    Benninger LA; Trillo C; Lascano J
    J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.
    Fiedorczuk K; Chen J
    Science; 2022 Oct; 378(6617):284-290. PubMed ID: 36264792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.
    Lehr CJ; Pilewski JM
    Curr Opin Organ Transplant; 2022 Jun; 27(3):198-203. PubMed ID: 35184094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
    Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
    Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021.
    Ringshausen FC; Sauer-Heilborn A; Büttner T; Dittrich AM; Schwerk N; Ius F; Nährlich L; Welte T; Greer M
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36517178
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CFTR modulators in special populations, part 3: Solid organ transplant.
    Kadouh NK; Elijah J; Fitzgerald LJ; Phan H
    Pediatr Pulmonol; 2023 Dec; 58(12):3393-3402. PubMed ID: 37067449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.
    Cimino G; Sorrenti S; Murciano M; Galoppi P; Ascenzioni F; Botta B; Brunelli R;
    Arch Gynecol Obstet; 2024 Jan; 309(1):9-15. PubMed ID: 36907900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy.
    Nuytten A; Prevotat A; Le Rouzic O; Dekemp J; Gilliot S; Gautier S; Le Duc K; Garabedian C
    Therapie; 2022; 77(6):743-745. PubMed ID: 35606190
    [No Abstract]   [Full Text] [Related]  

  • 19. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
    Laselva O; Bartlett C; Gunawardena TNA; Ouyang H; Eckford PDW; Moraes TJ; Bear CE; Gonska T
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.